Abstract: This disclosure describes markers that are associated with active tuberculosis (TB) and demonstrates that the disclosed markers can be used as a biomarker for determining whether a subject has or is at risk of having active TB and for the early detection of HIV-associated TB. This disclosure also provides methods of screening subjects who are thought to be at risk for developing active TB, methods of determining the efficacy of therapeutic regimens for preventing or treating active TB, and methods of identifying anti-TB agents.
Type:
Application
Filed:
October 2, 2020
Publication date:
October 13, 2022
Applicant:
Albert Einstein College of Medicine
Inventors:
Jacqueline M. Achkar, Eustache Paramithiotis
Abstract: The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.
Type:
Grant
Filed:
August 15, 2019
Date of Patent:
October 11, 2022
Assignees:
396419 B.C. Ltd., Albert Einstein College of Medicine
Inventors:
Carl Erickson, Christopher P. Rusconi, Kevin G. McLure, Matthew Levy, Arijit Bhowmick
Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
October 4, 2022
Assignees:
Microbiotix, Inc., Albert Einstein College of Medicine, The Government of the United States as Represented by the Secretary of the Army
Inventors:
Terry L. Bowlin, Donald T. Moir, Kartik Chandran, John M. Dye, Jr., John D. Williams, Zachary D. Aron, Jay P. Barbor, Kelly N. Lively, Peter J. Nash, Debra M. Mills, Arnab Basu
Abstract: The disclosure provides polypeptides that specifically bind to HLA-DQ8 for treating Type 1 Diabetes (TID) and methods using same for reducing autoimmune destruction of pancreatic islet beta cells. In particular, the present disclosure relates to peptides containing at least one D-amino acid that are capable of blocking the presentation of antigenic islet peptides (e.g., lnsB:9-23) by HLA-DQ8, and to their uses, especially as it relates to the prevention and/or treatment of TID.
Type:
Application
Filed:
August 4, 2020
Publication date:
September 29, 2022
Applicants:
Icahn School of Medicine at Mount Sinai, Montefiore Medical Center, Albert Einstein College of Medicine, Inc.
Inventors:
Yaron Tomer, Roman Osman, Angela Lombardi
Abstract: Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11a variants of Mena.
Type:
Application
Filed:
September 16, 2021
Publication date:
August 11, 2022
Applicants:
Albert Einstein College of Medicine, Massachusetts Institute of Technology, IFO-Regina Elena Cancer Institute
Inventors:
John S. Condeelis, Sumanta Goswami, Frank Gertler, Paola Nistico
Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
Type:
Grant
Filed:
June 9, 2020
Date of Patent:
August 9, 2022
Assignees:
MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
Inventors:
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
Type:
Grant
Filed:
June 9, 2020
Date of Patent:
August 9, 2022
Assignees:
MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
Inventors:
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Z. Wec, Laura Walker
Abstract: Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill CMV or CMV-infected cells are also provided.
Abstract: This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.
Type:
Application
Filed:
May 20, 2020
Publication date:
July 28, 2022
Applicants:
Albert Einstein College of Medicine, Victoria Link Limited
Inventors:
Steven C. Almo, Tyler Grove, Lawrence D. Harris, Gary B. Evans
Abstract: Provided herein are antibodies that specifically bind Centrin-1 and methods of making the same, for use the treatment, prevention, detection, imaging, and diagnosis of cancers including pancreatic and prostate cancer.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
July 26, 2022
Assignees:
RADIMMUNE THERAPEUTICS, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
David J. Rickles, Ekaterina Dadachova, Ruth A. Bryan
Abstract: Methods and compositions are disclosed for rapid functional analysis of gene variants based on analysis of protein-protein and protein-nucleic acid interactions.
Abstract: This disclosure relates to compositions and methods of identifying, isolating, and modulating cells and tissues based on their cellular glycosaminoglycan pattern. In some aspects, provided are anti-GAG motif antibodies or antigen-binding fragments thereof and their use for determining a glycosaminoglycan (GAG) glycotype for a cell. Also provided are methods of isolating cells, identifying cells, detecting a disease or disorder, and/or treating a disease or disorder based on a cellular glycotype.
Type:
Application
Filed:
May 26, 2020
Publication date:
July 21, 2022
Applicant:
Albert Einstein College of Medicine
Inventors:
Hannes E. Buelow, Ulrich G. Steidl, Steven C. Almo, Robert A. Townley, Richard Pisczcaztowski, Ron Seidel, III
Abstract: Methods and compositions are provided for inhibiting or treating a viral infection in a subject using cell-impermeable inhibitors of Akt, scramblase and/or a phosphatidylserine.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
July 12, 2022
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Betsy C. Herold, Steven C. Almo, Natalia Cheshenko, Jeffrey Bryan Bonanno
Abstract: This disclosure provides methods and compositions for treating TTP based on transfusion of a relatively small number of genetically modified red blood cells. The genetically modified red blood cells express a fusion protein including a fragment of ADAMTS13 that is enzymatically active against von Willebrand factor (VWF). The fragments of ADAMTS13 can be resistant to the inhibitors, e.g., the auto-immune antibodies, which are responsible for the acquired form of TTP.
Type:
Application
Filed:
April 17, 2020
Publication date:
July 7, 2022
Applicant:
Albert Einstein College of Medicine
Inventors:
Eric Bouhassira, Khulan Batbayar, Karl Roberts
Abstract: Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
June 7, 2022
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
Abstract: The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
Type:
Grant
Filed:
May 17, 2017
Date of Patent:
May 24, 2022
Assignee:
Albert Einstein College of Medicine
Inventors:
Sarah C. Garrett-Thomson, Steven C. Almo, Ronald D. Seidel, III